1-(1-萘基甲基)-1H-吲哚-3-甲醛 | 151409-77-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 1-(1-萘基甲基)-1H-吲哚-3-甲醛
• 英文名称: 1-(1-naphthylmethyl)-1H-indole-3-carbaldehyde
• 英文别名: 1-(naphthalen-1-ylmethyl)-1H-indole-3-carbaldehyde；1-(naphthalen-1-ylmethyl)indole-3-carbaldehyde
• CAS: 151409-77-7
• 化学式: C₂₀H₁₅NO
• mdl: MFCD02070803
• 分子量: 285.345
• InChiKey: IJIPHJOFFJPRLX-UHFFFAOYSA-N

物化性质

• 沸点：
  527.2±33.0 °C(Predicted)
• 密度：
  1.14±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  22
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-(1-萘基甲基)-1H-吲哚-3-甲醛 、 丙二酸 在 哌啶 、 吡啶 、 盐酸 作用下， 以 水 为溶剂， 反应 12.0h， 以78.2%的产率得到(E)-3-(1-(naphthalen-1-ylmethyl)-1H-indol-3-yl)acrylic acid
  参考文献：
  名称：

  Design, synthesis and biological evaluation of thiazole- and indole-based derivatives for the treatment of type II diabetes

  摘要：

  Present studies have shown that the lipid carrier has a significant role in several aspects of metabolic syndrome in A-FABP/ap2-deficient mice, including type 2 diabetes and atherosclerosis. 38 Thiazole- and indole-based derivatives were synthesized and investigated for their inhibitory effects on the production of LPS-stimulated TNF-alpha. Among them, 12b exhibited an excellent inhibitory efficiency compared to BMS309403 (95% vs. 85%) at the concentration of 10 mu M and a binding affinity for ap2 with the apparent K-i values 33 nM. Oral administration of 12b at a dosage of 50 mg/kg effectively reduced the levels of plasma blood glucose, triglycerides, insulin, total cholesterol and alanine aminotransferase in high-fat/diet-induced obesity model. The results highlighted that 12b was a potent anti-diabetic agent. (C) 2012 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2012.03.006
• 作为产物：
  描述：

  3-吲哚甲醛 、 1-溴甲基萘 在 potassium hydroxide 作用下， 以 乙醇 、 丙酮 为溶剂， 反应 0.33h， 生成 1-(1-萘基甲基)-1H-吲哚-3-甲醛
  参考文献：
  名称：

  Design, synthesis and biological evaluation of thiazole- and indole-based derivatives for the treatment of type II diabetes

  摘要：

  Present studies have shown that the lipid carrier has a significant role in several aspects of metabolic syndrome in A-FABP/ap2-deficient mice, including type 2 diabetes and atherosclerosis. 38 Thiazole- and indole-based derivatives were synthesized and investigated for their inhibitory effects on the production of LPS-stimulated TNF-alpha. Among them, 12b exhibited an excellent inhibitory efficiency compared to BMS309403 (95% vs. 85%) at the concentration of 10 mu M and a binding affinity for ap2 with the apparent K-i values 33 nM. Oral administration of 12b at a dosage of 50 mg/kg effectively reduced the levels of plasma blood glucose, triglycerides, insulin, total cholesterol and alanine aminotransferase in high-fat/diet-induced obesity model. The results highlighted that 12b was a potent anti-diabetic agent. (C) 2012 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2012.03.006

文献信息

• ESTERS AND AMIDES AS PLA2 INHIBITORS
  申请人：——

  公开号：US20020019416A1

  公开（公告）日：2002-02-14

  1 The present invention relates to a novel fatty acid derivative of formula (I), wherein R 1 is acyl group; R 2 is acyl(lower)alkyl; R 3 is hydrogen, aryl(lower)alkyl, etc.; R 4 is acyl(lower)alkyl; and X is —O—, —NH— or formula (II) [wherein R 5 is lower alkyl, etc.]; and a pharmaceutically acceptable salt thereof, which is useful as a medicament; the processes for the preparation of said fatty acid derivative or a salt thereof; a pharmaceutical composition comprising said fatty acid derivative or a pharmaceutically acceptable salt thereof; etc.

  本发明涉及一种新颖的脂肪酸衍生物，其化学式为（I），其中R1是酰基；R2是酰基（较低）烷基；R3是氢，芳基（较低）烷基等；R4是酰基（较低）烷基；X为—O—，—NH—或化学式（II）[其中R5为较低烷基等]；及其药学上可接受的盐，可用作药物；制备所述脂肪酸衍生物或其盐的方法；包含所述脂肪酸衍生物或其药学上可接受的盐的药物组合物等。
• Esters and amides as PLA2 inhibitors
  申请人：——

  公开号：US20040063959A1

  公开（公告）日：2004-04-01

  The present invention relates to a novel fatty acid derivative of the following formula: 1 wherein R 1 is acyl group; R 2 is acyl(lower)alkyl; R 3 is hydrogen, aryl(lower)alkyl, etc; R 4 is acyl(lower)alkyl; and X is —O—, —NH— or 2 [wherein R 5 is lower alkyl, etc]; and a pharmaceutically acceptable salt thereof, which is useful as a medicament; the processes for the preparation of said fatty acid derivative or a salt thereof; a pharmaceutical composition comprising said fatty acid derivative or a pharmaceutically acceptable salt thereof; etc.

  本发明涉及以下式子的新型脂肪酸衍生物：1其中R1是酰基；R2是酰基（较低）烷基；R3是氢、芳基（较低）烷基等；R4是酰基（较低）烷基；X是—O—、—NH—或2[其中R5是较低烷基等]；以及其药学上可接受的盐，其作为药物具有用途；制备该脂肪酸衍生物或其盐的方法；包含该脂肪酸衍生物或其药学上可接受的盐的制药组合物等。
• NOUVEAUX DERIVES DE L'ADENOSINE, LEURS PROCEDES DE PREPARATION, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
  申请人：LABORATOIRES UPSA

  公开号：EP0623138B1

  公开（公告）日：1997-05-21
• US5229505A
  申请人：——

  公开号：US5229505A

  公开（公告）日：1993-07-20
• US5480983A
  申请人：——

  公开号：US5480983A

  公开（公告）日：1996-01-02